Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines

Journal of Medicinal Chemistry

Volumn 43, Issue 8, 2000, Pages 1563-1572

  Stanslas, Johnson ^a,c   Hagan, Damien J ^a   Ellis, Michael J ^a   Turner, Claire ^a   Carmichael, James ^a   Ward, Wynne ^a   Hammonds, Timothy R ^b   Stevens, Malcolm F G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c Universiti Putra Malaysia   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

1H 2,3 DIHYDROINDOLIZINO[7,6,5 KL]ACRIDINIUM CHLORIDE; ACRIDINE DERIVATIVE; AMSACRINE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER;

ACRIDINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MICROSCOPY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0034692170     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9909490     Document Type: Article

References (45)

1. Part 6: Bostock-Smith, C. E.; Giménez-Arnau, E.; Missailidis, S.; Laughton, C. A.; Stevens, M. F. G.; Searle, M. S. Molecular recognition between a new pentacyclic acridinium salt and DNA sequences investigated by optical spectroscopic techniques, proton nuclear magnetic resonance spectroscopy and molecular modeling. Biochemistry 1999, 38, 6723-6731.
2. Albert, A. The Acridines, 2nd ed.; Edward Arnold: London, 1966.
3. Albert, A. Selective Toxicity, 7th ed.; Chapman & Hall: London, 1985.
4. Denny, W. A.; Baguley, B. C. In Molecular Aspects of Anti-Cancer Drug-DNA Interaction; Neidle, S., Waring, M. J., Eds.; Macmillan: London, 1994; pp 270-311.
5. Baguley, B. C. DNA intercalating anti-tumour agents. Anti-Cancer Drug Des. 1991, 6, 1-35.
6. Gamage, S. A.; Spicer, J. A.; Atwell, G. J.; Finaly, G. J.; Baguley, B. C.; Denny, W. A. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents. J. Med. Chem. 1999, 42, 2383-2393.
7. Kohn, K. W. Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment - Fifteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1996, 56, 5533-5546.
8. Molinski, T. F. Marine pyridoacridine alkaloids: structure, synthesis, and biological chemistry. Chem. Rev. 1993, 93, 1825-1838.
9. Alvarez, M.; Salas, M.; Joule, J. A. Marine, nitrogen-containing heterocyclic natural products. Structures and synthesis of compounds containing quinoline and/or isoquinoline units. Heterocycles 1991, 32, 759-794. Alvarez, M. Synthesis of pyridoacridines. Heterocycles 1992, 34, 2385-2405.
10. Alvarez, M.; Salas, M.; Joule, J. A. Marine, nitrogen-containing heterocyclic natural products. Structures and synthesis of compounds containing quinoline and/or isoquinoline units. Heterocycles 1991, 32, 759-794. Alvarez, M. Synthesis of pyridoacridines. Heterocycles 1992, 34, 2385-2405.
11. Copp, B. R.; Jompa, J.; Tahir, A.; Ireland, C. M. New tetracyclic pyridoacridine alkaloids from the Indonesian Ascidian, Eusynstyela latericius. J. Org. Chem. 1998, 63, 8024-8026.
12. Fugman, B.; Steffan, B.; Steglich, W. Necatorone, an alkaloidal pigment from the gilled toadstool Lactarius necator (Agaricales). Tetrahedron Lett. 1984, 25, 3575-3578. Hilger, C. S.; Fugman, B.; Steglich, W. Synthesis of necatorone. Tetrahedron Lett. 1985, 26, 5975-5978. Klamann, J.-D.; Fugmann, B.; Steglich, W. Alkaloidal pigments from Lactarius necator and L. atroviridis. Phytochemistry 1989, 28, 3519-3523.
13. Fugman, B.; Steffan, B.; Steglich, W. Necatorone, an alkaloidal pigment from the gilled toadstool Lactarius necator (Agaricales). Tetrahedron Lett. 1984, 25, 3575-3578. Hilger, C. S.; Fugman, B.; Steglich, W. Synthesis of necatorone. Tetrahedron Lett. 1985, 26, 5975-5978. Klamann, J.-D.; Fugmann, B.; Steglich, W. Alkaloidal pigments from Lactarius necator and L. atroviridis. Phytochemistry 1989, 28, 3519-3523.
14. Fugman, B.; Steffan, B.; Steglich, W. Necatorone, an alkaloidal pigment from the gilled toadstool Lactarius necator (Agaricales). Tetrahedron Lett. 1984, 25, 3575-3578. Hilger, C. S.; Fugman, B.; Steglich, W. Synthesis of necatorone. Tetrahedron Lett. 1985, 26, 5975-5978. Klamann, J.-D.; Fugmann, B.; Steglich, W. Alkaloidal pigments from Lactarius necator and L. atroviridis. Phytochemistry 1989, 28, 3519-3523.
15. Hagan, D. J.; Giménez-Arnau, E.; Schwalbe, C. H.; Stevens, M. F. G. Antitumour polycyclic acridines. Part 1. Synthesis of 7H-pyrido- and 8H-quino-[4,3,2-kl]acridines by Graebe-Ullmann thermolyses of 9-(1,2,3-triazol-1-yl)acridines: application of differential scanning calorimetry to predict optimum cyclisation conditions. J. Chem. Soc., Perkin Trans. 1 1997, 2739-2746.
16. Hagan, D. J.; Chan, D.; Schwalbe, C. H.; Stevens, M. F. G. Antitumour polycyclic acridines. Part 3. A two-step conversion of 9-azidoacridine to 7H-pyrido[4,3,2-kl]acridines by Graebe-Ullmann thermolysis of substituted 9-(1,2,3-triazol-1-yl)acridines. J. Chem. Soc., Perkin Trans. 1 1998, 915-923.
17. Julino, M.; Stevens, M. F. G. Antitumour polycyclic acridines. Part 5. Synthesis of 7H-pyrido[4,3,2-kl]acridines with exploitable functionality in the pyridine ring. J. Chem. Soc., Perkin Trans. 1 1998, 1677-1684.
18. Fixler, N.; Demeunynck, M.; L'homme, J. Regioselective electrophilic substitution of 2-hydroxy and 2-methoxy substituted acridines. Application to the synthesis of pyrido[2,3,4-mn]-acridine. Synth. Commun. 1997, 27, 2311-2324.
19. Giménez-Arnau, E.; Missailidis, S.; Stevens, M. F. G. Antitumour polycyclic acridines. Part 2. Physicochemical studies on the interactions between DNA and novel polycyclic acridine derivatives. Anti-Cancer Drug Des. 1998, 13, 125-143.
20. Giménez-Arnau, E.; Missailidis, S.; Stevens, M. F. G. Antitumour polycyclic acridines. Part 4. Physicochemical studies on the interactions between DNA and novel tetracyclic acridine derivatives. Anti-Cancer Drug Des. 1998, 13, 431-451.
21. Mair, A. C.; Stevens, M. F. G. Azidoacridines: potential nucleic acid mutagens. J. Chem. Soc., Perkin Trans. 1 1972, 161-165.
22. Reynolds, G. A. The reaction of organic azides with benzyne. J. Org. Chem. 1964, 29, 3733-3734.
23. Mitchell, G.; Rees, C. W. Cyclo-octa[def]carbazole: a new heterocyclic paratropic ring system. J. Chem. Soc., Perkin Trans. 1 1987, 403-412.
24. Abramovitch, R. A.; Chinnasmay, P.; Evertz, K.; Huttner, G. Cyclization of arylnitrenium ions to the apomorphine ring system: remarkable formation of a sixteen-membered ring by an intramolecular electrophilic aromatic substitution. J. Chem. Soc., Chem. Commun. 1989, 3-5. Scriven, E. F. V.; Turnbull, K. Azides: their preparation and synthetic uses. Chem. Rev. 1988, 88, 298-368. Stevens, M. F. G.; Shi, D.-F.; Castro, A. Antitumour benzothiazoles. Part 2. Formation of 2,2′-diaminobiphenyls from the decomposition of 2-(4-azidophenyl)benzothiazoles in trifluoromethane sulfonic acid. J. Chem. Soc., Perkin Trans. 1 1996, 83-93.
25. Abramovitch, R. A.; Chinnasmay, P.; Evertz, K.; Huttner, G. Cyclization of arylnitrenium ions to the apomorphine ring system: remarkable formation of a sixteen-membered ring by an intramolecular electrophilic aromatic substitution. J. Chem. Soc., Chem. Commun. 1989, 3-5. Scriven, E. F. V.; Turnbull, K. Azides: their preparation and synthetic uses. Chem. Rev. 1988, 88, 298-368. Stevens, M. F. G.; Shi, D.-F.; Castro, A. Antitumour benzothiazoles. Part 2. Formation of 2,2′-diaminobiphenyls from the decomposition of 2-(4-azidophenyl)benzothiazoles in trifluoromethane sulfonic acid. J. Chem. Soc., Perkin Trans. 1 1996, 83-93.
26. Abramovitch, R. A.; Chinnasmay, P.; Evertz, K.; Huttner, G. Cyclization of arylnitrenium ions to the apomorphine ring system: remarkable formation of a sixteen-membered ring by an intramolecular electrophilic aromatic substitution. J. Chem. Soc., Chem. Commun. 1989, 3-5. Scriven, E. F. V.; Turnbull, K. Azides: their preparation and synthetic uses. Chem. Rev. 1988, 88, 298-368. Stevens, M. F. G.; Shi, D.-F.; Castro, A. Antitumour benzothiazoles. Part 2. Formation of 2,2′-diaminobiphenyls from the decomposition of 2-(4-azidophenyl)benzothiazoles in trifluoromethane sulfonic acid. J. Chem. Soc., Perkin Trans. 1 1996, 83-93.
27. Ohta, T.; Machida, R.; Takeda, K.; Ende, Y.; Shudo, K.; Okamoto, T. Reductive phenylation of nitroarenes. J. Am. Chem. Soc. 1980, 102, 6385-6386.
28. Giaccone, G.; Gadzar, A. F.; Beck, H.; Zunino, F.; Capranico, G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res. 1992, 52, 1686-1674. Kasahara, K.; Fujiwara, Y.; Sugimoto, Y.; Nishio, K.; Tamura, T.; Matsuda, T.; Saijo, N. Determinants of response to the DNA topoisomerase II inhibitors adriamycin and etoposide. J. Natl. Cancer Inst. 1992, 84, 113-118. Kaufman, S. H.; Karp, J. E.; Jones, R. J.; Miller, C. B.; Schneider, E.; Zwelling, L. A.; Cowan, K.; Wendel, K.; Burke, P. J. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukaemia. Blood 1994, 83, 517-530.
29. Giaccone, G.; Gadzar, A. F.; Beck, H.; Zunino, F.; Capranico, G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res. 1992, 52, 1686-1674. Kasahara, K.; Fujiwara, Y.; Sugimoto, Y.; Nishio, K.; Tamura, T.; Matsuda, T.; Saijo, N. Determinants of response to the DNA topoisomerase II inhibitors adriamycin and etoposide. J. Natl. Cancer Inst. 1992, 84, 113-118. Kaufman, S. H.; Karp, J. E.; Jones, R. J.; Miller, C. B.; Schneider, E.; Zwelling, L. A.; Cowan, K.; Wendel, K.; Burke, P. J. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukaemia. Blood 1994, 83, 517-530.
30. Giaccone, G.; Gadzar, A. F.; Beck, H.; Zunino, F.; Capranico, G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res. 1992, 52, 1686-1674. Kasahara, K.; Fujiwara, Y.; Sugimoto, Y.; Nishio, K.; Tamura, T.; Matsuda, T.; Saijo, N. Determinants of response to the DNA topoisomerase II inhibitors adriamycin and etoposide. J. Natl. Cancer Inst. 1992, 84, 113-118. Kaufman, S. H.; Karp, J. E.; Jones, R. J.; Miller, C. B.; Schneider, E.; Zwelling, L. A.; Cowan, K.; Wendel, K.; Burke, P. J. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukaemia. Blood 1994, 83, 517-530.
31. Houlbrook, S.; Harris, A. L.; Carmichael, J.; Stratford, I. J. Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines. Anticancer Res. 1996, 16, 1603-1610.
32. Houlbrook, S.; Addison, C. M.; Davies, S. L.; Carmichael, J.; Stratford, I. J.; Harris, A. L.; Hickson, I. D. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br. J. Cancer 1995, 72, 1454-1461.
33. Monks, A.; Scudiero, D. A.; Johnson, G. S.; Paull, K. D.; Sausville, E. A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anti-Cancer Drug Des. 1997, 12, 533-541.
34. Wang, H.; Jiang, Z.; Wong, Y. W.; Dalton, W. S.; Futscher, B. W.; Chan, V. T.-W. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIα in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem. Biophys. Res. Commun. 1997, 237, 217-224.
35. Fairchild, C. R.; Ivy, S. P.; Kao-Shan, C.-S.; Whang-Peng, J.; Rosen, N.; Israel, M. A.; Melera, P. W.; Cowan, K. H.; Goldsmith, M. E. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res. 1987, 47, 5141-5148.
36. Wasserman, R. A.; Austin, C. A.; Fisher, L. M.; Wang, J. C. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase IIα in yeast. Cancer Res. 1993, 53, 3591-3596.
37. Meczes, L. M.; Marsh, K. L.; Fisher, L. M.; Rogers, M. P. Austin, C. A. Complementation of temperature sensitive topoisomerase II mutations in S. cerevisiae by a human TOPIIβ contruct allows study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother. Pharmacol. 1997, 39, 367-375.
38. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. J.; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubinstein, L. V.; Anderson, N. L.; Buolamwini, J. K.; van Osdol, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Johnson, G. S.; Wittes, R. E.; Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275, 343-349.
39. Stanslas, J.; Marsh, K. L.; Austin, C. A.; Robins, R. A.; Price, M. R.; Double, J. A.; Stevens, M. F. G. Antitumour properties of novel aza-polycyclic compounds. Br. J. Cancer 1998, 78, (S1) P32. Bostock-Smith, C. E.; Stanslas, J.; Giménez-Arnau, E.; Missailidis, S.; Laughton, C. A.; Searle, M. S.; Stevens, M. F. G. Noncovalent encounters between DNA and a new pentacyclic heteroaromatic salt and the biological sequelae. Proc. Am. Assoc. Cancer Res. 1999, 40, P32.
40. Stanslas, J.; Marsh, K. L.; Austin, C. A.; Robins, R. A.; Price, M. R.; Double, J. A.; Stevens, M. F. G. Antitumour properties of novel aza-polycyclic compounds. Br. J. Cancer 1998, 78, (S1) P32. Bostock-Smith, C. E.; Stanslas, J.; Giménez-Arnau, E.; Missailidis, S.; Laughton, C. A.; Searle, M. S.; Stevens, M. F. G. Noncovalent encounters between DNA and a new pentacyclic heteroaromatic salt and the biological sequelae. Proc. Am. Assoc. Cancer Res. 1999, 40, P32.
41. Hudson, R. F.; Chopard, P. A. U.S. Patent 3294820, 1963; Chem. Abstr. 1967, 66, 104827d.
42. Hudson, R. F.; Chopard, P. A. U.S. Patent 3294820, 1963; Chem. Abstr. 1967, 66, 104827d.
43. Atwell, C. J.; Cain, B. F.; Seelye, R. N. Potential antitumor agents. 12. 9-Anilino-acridines. J. Med. Chem. 1972, 15, 611-615.
44. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 13, 91-109.
45. Hammonds, T. R.; Maxwell, A. The DNA dependence of the ATPase activity of human DNA topoisomerase IIα. J. Biol. Chem. 1997, 272, 32696-32703.